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Despite classical identiﬁcation of immune response impairment in sarcoidosis, such as anergy to delayed
skin tests, the characterization of contributing mechanisms are still uncertain and infectious events
complicating the course of the disease are unfrequent. Rarely, additional quantitative T-cell defects are
reported in association with the disease. Although mechanisms of lymphocyte disorders are unknown,
lymphocytopenia is usually revealed by an opportunistic infection.
We report the case of an 18-year-old man, with pulmonary sarcoidosis, treated by corticoids, who
developed cryptococcal meningitis. A CD4þ T-cell defect was simultaneously discovered, which was not
inﬂuenced by corticoid arrest, persisted following infection resolution and control of sarcoidosis. In vitro
experiments were performed in parallel, demonstrating a restricted CD4þ T-cell proliferation hypo-
responsiveness to both IL-2 and lectin. In addition, rhIL-2 subcutaneously administrated failed to restore
peripheral T-cell count.
A multi-visceral sarcoidosis associated to CD4-lymphocytopenia is rarely reported and highly demon-
strative of the related risk for an opportunistic infection development. In context, the absence of lectin
and IL-2 effects on in vitro CD4þ T-cell proliferation assays and the inefﬁciency of in vivo rhIL-2 on T-cell
count have been infrequently reported and suggested the presence of a defective intracellular signaling
pathway, responsible for T cell defect.
 2009 Elsevier Ltd. All rights reserved.1. Introduction
Sarcoidosis is characterized by the presence of diffuse non-
caseating granulomas, which are constituted by a peripheral ring of
T- and B-cells. This local inﬂammation in multiple organs is coun-
terbalanced by an anergy to delayed tuberculin skin test.1–4 This
dual immune response has been recognized for a long time and is
considered as an unresolved immunological paradox. Recent
advances in immunology have addressed this question and pointed
out a role of regulatory CD4þ CD25þ FoxP3þ T-cell.5
Although the presence of this qualitative peripheral T-cell defect
is well-established in sarcoidosis, additional effects of corticoids on
T-cell-associated immune response have been reported.6–9 Alter-
natively, a quantitative T-lymphocytopenia is rarely described in
sarcoidosis, usually revealed by an opportunistic infection.9
Mechanisms of this T-cell defect remain rarely investigated and no
deﬁnitive explanations have been provided.x: þ33 4 78 86 33 45.
. Devouassoux).
rved.We reported a case report of pulmonary sarcoidosis, associated
to a severe, persistent and quantitative CD4þ T-cell defect. This
latter was revealed by a Cryptococcus neoformans meningitis. Our
data, showing an in vitro hypo-responsiveness of CD4þ T-cell to IL-
2 and phytohaemagglutinin (PHA), suggested the presence of
alternative impaired intracellular signaling pathways-related T-cell
in sarcoidosis. This hypothesis was reinforced by the absence of in
vivo rhIL-2 effect on CD4þ T-cell count.2. Materials and methods
2.1. Assessment of T-cell count
EDTA whole blood was lysed by Optilyse reagent (Beckman-
Coulter, Miami, USA), then incubated for 15 minwith anti-CD4-FITC,
anti-CD8-PE and anti-CD3-PC5 monoclonal antibodies (BD, Pont
de Claix, France). Stained cells were analyzed on a XL-MCL ﬂow
cytometer (Beckman-Coulter, Miami, USA). Total lymphocyte count
was determined by an automated hematology analyzer and T-cell
subsets were calculated as follows: (% CD3 or CD4 or CD8) total
lymphocyte count.
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phytohaemagglutinin (PHA) and IL2
PBMC were isolated by Ficoll-Paque density gradient centrifu-
gation (PAA laboratories, Pasching, Austria), then cultured (106/ml)
at 37 C (5% CO2), in RPMI 1640 with 25 mM HEPES, 2 mM L-
glutamine (Invitrogen life technologies, Cergy Pontoise, France),
10% human heat-inactivated AB serum (EFS, Lyon, France) and
antibiotics (Sigma-Aldrich, Lyon, France) in ﬂat-bottom 96 well
plates. PBMC were stimulated either for 48 h with 10 mg/ml of PHA
(Oxoid, Dardilly, France) or for 5 days with 20 U/ml of rhIL-2 (Roche
Applied Science, Indianapolis, USA) with or without PHA.
To assess lymphocyte proliferation, 10 mCi/mL of [methyl-3H]-
Thymidine [2,0 Ci/mmol] (GE Healthcare Europe, Orsay, France)
was added 24 h before harvesting cells on a ﬁberglass ﬁlter using an
automated cell harvester. Incorporated radioactivity was measured
in a direct beta counter (PerkinElmer life and Analytical Sciences,
Courtaboeuf, France). The results are expressed as mean cpm SD
of triplicates.
2.3. Staining of PBMC and ﬂow cytometry experiments
Freshly isolated PBMC were stained with anti-CD4-FITC, anti-
CD8-FITC, anti-CD25-PE or anti-CD132-PE and anti-CD3-PECy5
monoclonal antibodies (BD, Pont de Claix, France) for 15 min, then
washed and resuspended in PBS containing 0.6% formaldehyde.
After 48 h (PHA) or 5 days (rhIL-2 or rhIL-2þ PHA) of stimulation,
PBMC were washed with PBS and stained with monoclonal anti-
bodies, as previously described. Typically, 100,000 to 500,000 total
events were acquired on ﬂow cytometer.
2.4. Observation
An 18-year-old white patient, non-smoker was hospitalized
for an increasing dyspnea, mediastinal lymph nodes enlargement
and pulmonary inﬁltrates on chest radiograph. CT scan conﬁrmed
the presence ofmediastinal lymphnodes and alveolar opacities. The
serum angiotensin-converting enzyme was augmented (193 IU/l).
Anergy to tuberculin skin test was present. The broncho-alveolar
lavage ﬂuid contained 86%macrophages and 14% lymphocytes (20%
CD4þ cells and 80% CD8þ cells). Pathological examination of
inguinal lymph node was consistent with the diagnosis of sarcoid-
osis. Corticoids were introduced (40 mg/d, one month), then
progressively decreased until 20 mg/d. Three months later, the
patient was asymptomatic and chest x ray was normalized.
Seven months later, he was admitted to Emergency department
with fever, headache and vomiting. Brain magnetic resonance
imagery (MRI) showed multiple abscesses. Lumbar puncture yiel-
ded pleocytosis (107 cells per cubic millimeter, 70% of lymphocyte)
and a protein concentration of 1 g/l. Stainingwith India ink revealed
encapsulated yeasts, consistent with Cryptococcus neoformans
meningitis. Speciﬁc antigen was detected on peripheral blood and
cerebrospinal ﬂuid. Additionally a total lymphocyte count of
0.430109/l, with a CD4þ T-cells count of 94 per cubic millimeter
was discovered. Tests for HIV 1 and 2 antibodies were negative and
immunoglobulins were normal. Corticoids were stopped and
treatment with amphotericin B (70 mg/d) and ﬂucytosine (8 g/d)
was initiated. Clinical outcomes improved progressively, and cere-
bral MRI was normalized at 6 weeks, leading to switch amphoter-
icin B for itraconazole (200 mg/d). Lymphocytopenia remained
unmodiﬁed during this period. At that time, a hypercalcemia and
a granulomatous medullar inﬁltration argued for an active
sarcoidosis and corticosteroids were reinitiated (40 mg/d), with
a rapid normalization of calcium abnormalities. However, lym-
phocytopeniawas not inﬂuenced (lymphocyte count of 0.59109/l,CD4þ T-cells count of 119 per cubic millimeter) and a primary
prophylaxis against Pneumocystis jiroveci was started. Flucytosine,
itraconazole and corticoids were deﬁnitively stopped 9 months, 3
and 5 years later respectively. Despite a persistent CD4þ lympho-
cytopenia, no other opportunistic infection occurred.
To explore pathogenesis of lymphocytopenia, T-cells were ﬁrst
tested in vitro for IL-2R expression by ﬂow cytometry. Spontane-
ously, CD25 (IL-2R a chain) and CD132 (IL-2R g chain) were
expressed by 3% and 91% of CD3þ cells respectively (normal ranges
<2% and 85–99% respectively). In the presence of PHA, a chain was
expressed by the total CD3 and CD4 cell populations. Secondly,
using pulsing cultures with [3H] thymidine, T-cell proliferationwas
examined in the presence of PHA and/or IL-2. PHA alone was
responsible for an increased T-cell proliferation, which peaked at
48 h (16,100 620 cpm). Addition of IL-2 was associated with
a maintained T-cell proliferation at 5 days of culture
(15,306 986 cpm vs 6391389 cpm). Identical results were
observed in normal control. Finally, employing ﬂow cytometry, we
sought to identify proliferation assay-related T-cell subtypes. At
5 days of culture, IL-2 induced a proliferation responseof both CD3þ
andCD8þ cells inpatient (63–90% and 46–91% respectively). Similar
responses were observed using PHA or PHAþ IL-2 stimulations, in
both patient and control. By contrast, PHA or PHAþ IL-2 induced
weak CD4þ cell proliferation responses (17–29%) and IL-2 alonewas
responsible for a depressed CD4 response in patient (17–2%).
Finally, following the control of both sarcoidosis and crypto-
coccal meningitis, a rhIL-2 therapy was initiated (95,000 IU subcu-
taneous) weekly. After 5 months of treatment, lymphocytopenia
and CD4þ cell counts were not modiﬁed and rhIL-2 was stopped.
3. Discussion
We reported a Cryptococcus neoformansmeningitis, occurring in
context of sarcoidosis and CD4þ T-lymphocytopenia. Although
CD4þ T-cell defect was diagnosed during an opportunistic infection
and after months of corticoids treatment, lymphocytopenia
appeared independent of both steroids and fungal infection.
Besides this case report, we described additional in vitro T-cell
investigations, suggesting 1) a normal proﬁle of IL-2R expression by
T-cells, 2) a normal total T-cell proliferation response and 3) an in
vitro restricted hypo-responsiveness of CD4þ cells to both mito-
genic lectin PHA and rIL-2 stimulations. This latter in vitro obser-
vation was in line with the absence of in vivo rhIL-2 effect on
peripheral blood CD4þ T-lymphocytopenia.
Infectious diseases occurring in sarcoidosis have been previ-
ously carefully investigated, suggesting a weak frequency of
opportunistic infections.6–8 Additionally, an exhaustive review of
65 opportunistic infections complicating sarcoidosis underlined
a facilitating role of corticoids (50% of cases) and the over-
representation of Cryptococcus neoformans.9
Extra-pulmonary cryptococcal infections are mainly described
in immuno-compromised patients and HIV-seropositive patients
are particularly exposed.10 Several lines of evidence argue for
a critical role of T-cell-mediated immunity impairment in crypto-
coccal diseases. Firstly, cryptococcal meningitis occurs in
profoundly immunosuppressed patients.11 Secondly, prevalence of
infection has declined with the introduction of antiretroviral
therapy.12 Finally, cryptococcal infections have been reported in
other situations of T-cell defect, including autoimmune disease,
idiopathic lymphocytopenia and sarcoidosis.13–15
T-cell lymphocytopenia in sarcoidosis is thought to be a rare
disorder, usually recognized in the presence of an infectious compli-
cation.9 Since peripheral T-cell count is rarely documented, an
underestimation of T-cell defect in sarcoidosis is expected. Sarcoid-
osis-related peripheral T-cell lymphocytopenia is classically linked to
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described, which is rapidly corrected by corticoids. This hypothesis is
proposed to explain anergy to delayed cutaneous hypersensitivity
tests and T-cell overrepresentation at the site of granuloma forma-
tion.1,2 However, the question of the origin of T-cell excess in the lung
remainsspeculative, betweena localproliferationof lymphocytesand
a recruitment at the site of disease.16 Recently, a role for CD4þ CD25þ
FoxP3 regulatory T-cells has been proposed. Although regulatory T-
cells were presented in BAL ﬂuid, in peripheral blood and in sarcoid
granuloma, the anti-proliferative activity induced dissociated effects
on cytokineproduction,with a complete abolitionof T-cell-related IL-
2 production and a reduction of T-cell-related TNF-a production.
Results might be of interest to explain the simultaneous peripheral
anergy and the maintenance of granuloma formation in the lung
respectively.5 Secondly, in corticoid-treated sarcoidosis, a peripheral
lymphocytopenia as a consequence of an immune suppression is also
well-described.3,4
Our data are difﬁcult to conciliate with both previous theories.
Indeed, frequencies of lymphocytes and CD4þ T-cells were weak in
the initial broncho-alveolar lavage. At that time, peripheral CD4-
lymphocytopenia was unknown, but such BAL features were in
disagreement with an initial pulmonary compartmentalization of
lymphocyte. In addition, following arrest of corticoids, peripheral
CD4þ T-cell defect persisted, suggesting a corticoid-independent
effecton lymphocyte count. Finally, althoughourdatadidnotallowus
to evaluate regulatory T-cell, the anti-proliferative effect of regulatory
T-cells has not been associated to a quantitative CD4þ T-cell defect.5
There is compelling evidence for a determinant role of IL-2 in
sarcoidosis pathogenesis. Firstly, IL-2 mRNA and protein are
elevated in BAL ﬂuid and in lung cell of sarcoidosis.17 Secondly,
patients with higher levels of IL-2 secretion by BAL cells or higher
serum levels of soluble IL-2 receptor may be more likely to have
active disease.18,19 Additionally, effects of IL-2 on T-cells are
demonstrative. In HIV-seropositive patients, it has been demon-
strated that administration of IL-2 was associated with an increase
of CD4þ T-cells.20 Furthermore, sarcoidosis development following
treatment with IL-2 has been reported in HIVþ patients.21 In the
same way, an increased activity of sarcoidosis was reported after
employment of IL-2 for the treatment of a renal cancer.22
Our data demonstrating in context of sarcoidosis, a CD4þ T-cell
hyporesponsiveness to IL-2 and PHA suggest alternative explanations
for T-cell lymphocytopenia. It has been shown that mitogen cross-
linking of the receptor CD3 and IL-2/IL-2R interaction initiated T-cell
proliferation.23 Binding of mitogenic lectin to T-cell receptor induced
a lectin signal transduction, involving G protein activation,24 directly
implicated in the modulation of mitogenic response via cAMP
synthesis.25 A sustained elevation of cAMP suppresses both early
events following TCR stimulation26 and progression through cellular
cycle following IL-2/IL-2R interaction.27 Whereas it has been docu-
mented that IL-2R expression by T-cell and that lectin recognition by
CD3 T-cell receptor were not impaired in sarcoid blood T-cell,28
a defect located at any point of the subsequent signal transduction
pathwayof the cell activationprocessmight be implicated in the poor
response of T-cell to PHA and IL-2. A dysfunction of G protein29 and/
or a dysregulation of intracellular cAMP levels, associated to an
abnormal degradative enzyme phosphodiesterase pathway30 have
been documented in sarcoidosis and might be responsible for qual-
itative and/or quantitative defect of peripheral blood T-cell.
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